Skip to main content
Premium Trial:

Request an Annual Quote

UC Davis, Whitney Laboratory, DNAStar

Premium
UC Davis Fiehn Laboratory to Use Genedata’s Refiner MS and Analyst Software
 
Genedata will partner with the Fiehn Laboratory at the University of California, Davis to provide the former’s Expressionist software platform for biomarker discovery. Both Refiner MS and Analyst modules will be used for mass spectrometry-based metabolomics analyses to classify patient samples and identify biomarkers.
 
Genedata’s Refiner MS software module performs high-throughput processing and automated quality analysis of mass spectrometry-based proteomics and metabolomics data. Refiner MS affords rapid processing of hundreds of gigabytes of data simultaneously, while Analyst touts a comprehensive statistical analysis platform that allows these processed data to be compared with microarrays, bead-based assays, qPCR, 2D-PAGE, 2D-DIGE and NMR data, as well as additional types of MS data. This integrated view helps researchers to understand the action of all biomolecules in a single, comprehensive system, the company said. 
 

 
Whitney Lab for Marine Bioscience and DNAStar
Sign Software Site License Agreement
 
DNAStar has signed a site license agreement with the Whitney Laboratory for Marine Bioscience in St. Augustine, Fla.,for the use of the company’s Lasergene sequence analysis software. Under terms of the agreement, scientists at the institute will be able to use the most current version of DNAStar’s Lasergene software for four years.   
 
Lasergene is a comprehensive suite of tools for molecular biologists and geneticists. It is used primarily in the assembly and analysis of DNA and protein sequences.
 

Currently, DNASTAR produces Lasergene, a sequence analysis software suite; GenVision, a data visualization software application; and ArrayStar, a microarray gene expression visualization tool. 

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.